Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds
(Thomson Reuters ONE) -
SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a
wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and
a global drug discovery and development services company providing translational
platforms to advance oncology, inflammation, cardiovascular and metabolic
disease research, will showcase their scientific expertise at this year's
American Association for Cancer Research's International Conference on Molecular
Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26(th) through the
30(th).
CrownBio's scientists will present 13 scientific posters describing their latest
research efforts, including generation of novel models for combinatory
chemotherapy and immunotherapy studies, creation of 3D screening panels for
improved efficacy assessments, demonstration of a checkpoint immunotherapy
modulating intestinal microbiota, among other innovative developments in cancer
therapeutics and preclinical pharmacology evaluation.
On Saturday October 28(th), Crown Bioscience's Dr. Henry Li will deliver an oral
presentation entitled, "Transcriptomic analysis of patient-derived xenografts
reveals heterogeneity in human and mouse stroma/immune compartments", as part of
the conference's Challenges and Opportunities of Genomic Based Clinical Trials
Plenary Session.
"I am excited to share Crown Bioscience's cutting-edge research with colleagues
at AACR- NCI-EORTC," said Dr. Henry Li, Crown Bioscience's Vice President of
Translational Oncology. "The data presented will exhibit the utility of our
clinically relevant PDX models to identify critical biomarkers and improve
preclinical evaluation of cancer therapies."
"Crown Bioscience is honored to play a leading role in presenting opportunities
for scientific advancements at AACR-NCI-EORTC," said Laurie Heilmann, Chief
Business Officer. "The work of our dedicated scientific team exemplifies Crown
Bioscience's commitment to helping researchers solve global health challenges
through continued innovation of our scientific translational platform."
Delegates can request copies of the posters and learn more about Crown
Bioscience's scientific translational platform at booth 601.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology, inflammation and
metabolic disease research. With an extensive portfolio of relevant models and
predictive tools, Crown Bioscience enables clients to deliver superior clinical
candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
marketing(at)CrownBioscience.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via GlobeNewswire
Datum: 17.10.2017 - 16:12 Uhr
Sprache: Deutsch
News-ID 564041
Anzahl Zeichen: 3374
contact information:
Town:
Santa Clara
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 442 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds"
steht unter der journalistisch-redaktionellen Verantwortung von
Crown Bioscience Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
